Back to News
Market Impact: 0.2
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
Source: zacks.com
Analyst EstimatesMarket Technicals & FlowsHealthcare & Biotech
United Therapeutics (UTHR) recorded an outsized move in the prior session alongside above-average trading volume. However, recent earnings-estimate revision trends may constrain further near-term share-price gains, creating a cautious outlook despite the stock's momentum.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
UTHR-0.30
More News
- United Therapeutics CEO Martine Rothblatt disposes of $3.9m in stock
- Cantor Fitzgerald reiterates United Therapeutics stock rating after patent win
- Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more
- US borrowing costs hit 24-year high as global bond sell-off intensifies
- These charts show how volatile the last quarter was for stocks and bonds
- $8.2B acquisition validates AI-picked chip stock: +20% since June
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Independent Research Firms: A Publishing System
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More